ReviewVirus genes2017
Ebola and Marburg virus vaccines.
Review in Virus genes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 117 citations in OpenAlex.
- Characterization of Ravn virus viral shedding dynamics in experimentally infected Egyptian rousette bats (Journal of virology · 2025Article
- In-silico repurposing of antiviral compounds against Marburg virus: a computational drug discovery approach.In silico pharmacology · 2025Article
- In silico design of Ebola virus Glycoprotein antigenic peptides as vaccine candidates.PloS one · 2025Article
- Filovirus vaccines as a response paradigm for emerging infectious diseases.NPJ vaccines · 2024Review
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Can Marburg virus be sexually transmitted?Health science reports · 2024Article
- Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies.BMC biotechnology · 2024Article
- Strengthening global health resilience: Marburg virus-like particle vaccines and the One Health approach.Science in One Health · 2024Review
- Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus.Emerging microbes & infections · 2023Article
- Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation.The Journal of infectious diseases · 2023Review
- The looming threat of Marburg disease outbreak in Tanzania, East Africa - an Editorial.Annals of medicine and surgery (2012) · 2023Article
- Article
- Marburg virus disease treatments and vaccines: recent gaps and implications.Annals of medicine and surgery (2012) · 2023Article
- Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.Lancet (London, England) · 2023Article
- Review
- Preparing for future outbreaks in Ghana: An overview of current COVID-19, monkeypox, and Marburg disease outbreaks.Health promotion perspectives · 2023Review
- Marburg virus disease: the paradox of Nigeria's preparedness and priority effects in co-epidemics.Bulletin of the National Research Centre · 2023Review
- Recent outbreak of Marburg virus disease: Could it be a threat for global public health?Health science reports · 2023Article
- Pathogenicity and virulence of Marburg virus.Virulence · 2022Review
- Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The filoviruses, Ebola virus (EBOV), and Marburg virus (MARV), are among the most pathogenic viruses known to man and the causative agents of viral hemorrhagic fever outbreaks in Africa with case fatality rates of up to 90%. Nearly 30,000 infections were observed in the latest EBOV epidemic in West Africa; previous outbreaks were much smaller, typically only affecting less than a few hundred people. Compared to other diseases such as AIDS or Malaria with millions of cases annually, filovirus hemorrhagic fever (FHF) is one of the neglected infectious diseases. There are no licensed vaccines or therapeutics available to treat EBOV and MARV infections; therefore, these pathogens can only be handled in maximum containment laboratories and are classified as select agents. Under these limitations, a very few laboratories worldwide conducted basic research and countermeasure development for EBOV and MARV since their respective discoveries in 1967 (MARV) and 1976 (EBOV). In this review, we discuss several vaccine platforms against EBOV and MARV, which have been assessed for their protective efficacy in animal models of FHF. The focus is on the most promising approaches, which were accelerated in clinical development (phase I-III trials) during the EBOV epidemic in West Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.